Prospective Study of the Feedback From an Adherence Monitor on Asthma Control (INCA)

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Professor Richard Costello, Beaumont Hospital
ClinicalTrials.gov Identifier:
NCT01529697
First received: February 7, 2012
Last updated: February 8, 2012
Last verified: February 2012
  Purpose

Inhaled medications are the mainstay of the therapeutic management of respiratory disorders. Considered by many to be 'simple' and 'easy' to use, clinicians are aware that inhalers are often improperly used. However, there is no tool that can detect and record errors in either the timing or the method dose administration

The investigators designed a device that makes an acoustic record each time an inhaler is used. Opening the device makes an acoustic file which is recorded, this file is "time-stamped" which means that the timing of drug administration is recorded. When the device is retrieved and acoustic analysis performed, the steps involved in using the inhaler can be determined. Hence, the subjects inhaler technique is assessed and errors in the inhaler use identified. Together this means that errors in inhaler technique and timing of use can be quantified.

In this study the investigators attached the device to a discus dry powder inhaler. In order to eliminate the behavioral component of adherence and identify the mechanical issues associated with effective inhaler use the investigators studied subjects who were already in Hospital and already prescribed a discus inhaler. The investigators hypothesized that the device would identify which errors in technique were the most common and that this would provide insight into how these errors might be eliminated.


Condition Intervention
Asthma
Behavioral: Feedback from a computer log of use of the inhaler

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Study of the Feedback From an Adherence Monitor on Asthma Control

Resource links provided by NLM:


Further study details as provided by Beaumont Hospital:

Primary Outcome Measures:
  • Adherence rate [ Time Frame: at three months ] [ Designated as safety issue: No ]
    The rate of adherence at baseline and at the end of the study, which at the end of the 3 month of study will be assessed. The adherence will be the number of doses taken at the correct time. The correct time is twice a day, in a period not less than 6 hours between the last dose and the subsequent dose or at a time greater than 18 hours apart from the previous dose.


Secondary Outcome Measures:
  • Asthma quality of life score [ Time Frame: at 3 months ] [ Designated as safety issue: No ]
    The asthma quality of life score will be related to adherence, The baseline asthma quality of life score and the quality of life score at the end of three months will be subtracted and these will be correlated with the average rate of adherence over the three months.


Estimated Enrollment: 100
Study Start Date: February 2010
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Feedback from a computer log of use of the inhaler
    The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

This study will involve patients attending the respiratory clinic at Beaumont Hospital. Patients already prescribed salmeterol-fluticasone via a discus inhaler will be asked to participate.

Criteria

Inclusion Criteria:

  • Patients prescribed inhaled salmeterol/fluticasone

Exclusion Criteria:

  • Smokers
  • Allergy to salmeterol/fluticasone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01529697

Sponsors and Collaborators
Beaumont Hospital
Investigators
Principal Investigator: Richard Costello, MD Beaumont Hospital
  More Information

No publications provided

Responsible Party: Professor Richard Costello, Professor of Medicine, Beaumont Hospital
ClinicalTrials.gov Identifier: NCT01529697     History of Changes
Other Study ID Numbers: BeaumontH
Study First Received: February 7, 2012
Last Updated: February 8, 2012
Health Authority: Ireland: Irish Medicines Board

Keywords provided by Beaumont Hospital:
Asthma
Inhaler use

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on July 31, 2014